title: Role of endothelium-derived nitric oxide in the modulation of canine myocardial mitochondrial respiration in vitro. Implications for the development of heart failure.
abstract: The mechanism responsible for the regulation of cardiac function by endogenous nitric oxide (NO) remains unclear. In this investigation, O2 consumption by freshly isolated myocardial muscle segments from the left ventricular free wall of canine hearts was quantified by a Clark-type O2 electrode at 37 degrees C. S-nitroso-N-acetylpenicillamine (SNAP, 9 +/- 3% to 50 +/- 8%), bradykinin (BK, 14 +/- 3% to 30 +/- 5%), or carbachol (CCh, 15 +/- 4% to 29 +/- 4%) significantly attenuated tissue O2 consumption at doses of 10(-7) to 10(-4) mol/L (mean +/- SE, P < .05). The effects of BK and CCh, but not SNAP, were blocked by 10(-4) mol/L NG-nitro-L-arginine, consistent with both BK and CCh stimulating NO biosynthesis and with SNAP decomposing to release NO, respectively. Similar doses of 8-Br-cGMP caused a respiratory inhibition, but to a lesser extent (9 +/- 2% to 14 +/- 6%). A mitochondrial uncoupler, 2,4-dinitrophenol (at 1 mmol/L), blocked the effects of 8-Br-cGMP, but not those of SNAP, BK, or CCh, suggesting that the major site of action of NO is on mitochondrial electron transport. Myocardial muscle from dogs with pacing-induced heart failure had a basal O2 consumption rate of 251 +/- 21 nmol.min-1.g-1, which was 54% higher than the rate seen in muscle from normal healthy canine hearts. The inhibitory effects of BK and CCh on O2 consumption were not observed in failing cardiac tissue, but SNAP showed an unaltered inhibitory effect. Therefore, our results indicate that NO released from microvascular endothelium by BK, stimulation of muscarinic receptors, and perhaps flow velocity may play an important physiological role in the control of cardiac mitochondrial respiration, and the loss of this regulatory function may contribute to the development of heart failure.
authors.affiliation: Department of Physiology, New York Medical College, Valhalla 10595, USA.
authors.forename: Y W
authors.initials: YW
authors.lastname: Xie
authors.forename: W
authors.initials: W
authors.lastname: Shen
authors.forename: G
authors.initials: G
authors.lastname: Zhao
authors.forename: X
authors.initials: X
authors.lastname: Xu
authors.forename: M S
authors.initials: MS
authors.lastname: Wolin
authors.forename: T H
authors.initials: TH
authors.lastname: Hintze
mesh_terms: D019297:2,4-Dinitrophenol; D015124:8-Bromo Cyclic Adenosine Monophosphate / Q000494:pharmacology; D000818:Animals; D002303:Cardiac Output, Low / Q000209:etiology*; D004140:Dinitrophenols / Q000494:pharmacology; D004285:Dogs; D004730:Endothelium, Vascular / Q000378:metabolism*; D008929:Mitochondria, Heart / Q000378:metabolism*; D009206:Myocardium / Q000378:metabolism; D009569:Nitric Oxide / Q000502:physiology*; D010101:Oxygen Consumption / Q000187:drug effects; D012016:Reference Values; D014475:Uncoupling Agents / Q000494:pharmacology
chemical_list: D004140:Dinitrophenols; D014475:Uncoupling Agents; D015124:8-Bromo Cyclic Adenosine Monophosphate; D009569:Nitric Oxide; D019297:2,4-Dinitrophenol